These slides and the accompanying oral presentation contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "p

Oculis R&D Day: Retina July 11,

2023 Rethinking Ophthalmology Nasdaq: OCS Exhibit 99.1

These slides and the accompanying oral

presentation contain forward-looking statements and information. The use of words such as "may," "might," "will," "should," "expect," "plan," "anticipate,"

"believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward-looking statements.

For example, all statements we make regarding the initiation, timing, progress and results of: our expected cash runway; our preclinical studies and our clinical studies; our research and development programs; our regulatory strategy; our future

development plans; our ability to advance product candidates into, and successfully complete clinical trials; and the timing or likelihood of regulatory filings and approvals and statements regarding the potential therapeutic benefits of our product

candidates, are forward looking. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and

uncertainties that may cause actual results to differ materially from those that we expected. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the possibility that Oculis may be

adversely affected by economic, business, and/or competitive factors; Oculis' estimates of expenses and profitability; Oculis' ability to develop, manufacture and commercialize the product candidates in its pipeline; actions of regulatory

authorities, which may affect the initiation, timing and progress of clinical studies or future regulatory approvals or marketing authorizations; the ability of Oculis or its partners to enroll and retain patients in clinical studies; the ability of

Oculis or its partners to gain approval from regulators for planned clinical studies, study plans or sites; Oculis' ability to obtain and maintain regulatory approval or authorizations of its products, including the timing or likelihood of expansion

into additional markets or geographies; the success of Oculis' current and future collaborations, joint ventures, partnerships or licensing arrangements; and other risks and uncertainties set forth in the sections entitled "Risk Factors"

and "Cautionary Note Regarding Forward-Looking Statements" in documents that Oculis may from time to time file or furnish with the U.S. Securities and Exchange Commission (the "SEC"). Any forward-looking statement speaks only

as of the date on which it was made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. Copyright of this presentation is owned

by Oculis. No part of this presentation may be reproduced in any manner without the permission of Oculis. Safe Harbor Statements Cautionary Note on Forward-looking Statements

Agenda Opening Remarks Riad Sherif,

M.D. Chief Executive Officer 5mn OCS-01 Phase 3 DIAMOND Program in Diabetic Macular Edema: Stage 1 Recap and Next Steps Arshad Khanani, M.D., M.A. Sierra Eye Associates, University of Nevada; Co-PI for DIAMOND; Oculis SAB member David Boyer, M.D.

Keck School of Medicine, USC; Co-Principal investigator for DIAMOND; Oculis SAB member 15mn 15mn OCS-01 PoC LEOPARD Trial Cystoid Macular Edema Quan Dong Nguyen, MD, MSc, FARVO, FASRS Stanford University School of Medicine; Principal Investigator

for LEOPARD Trial ; Oculis SAB member 15mn OCS-05 PoC ACUITY Trial in Acute Optic Neuritis Sophie Bonnin, M.D. Rothschild Foundation Hospital, Paris 15mn Q&A Session Moderated by: Riad Sherif, M.D., CEO David Boyer, M.D. Arshad Khanani, M.D.,

M.A., Quan Dong Nguyen, MD, MSc, FARVO, FASRS Sophie Bonnin, M.D. Pravin Dugel, M.D., Oculis Director Sabri Markabi, M.D., Independent R&D Adviser Ramin Tadayoni, M.D., Paris University Pablo Villoslada, M.D., Stanford University Bastian Dehmel,

M.D., Oculis Head of Development 50mn Concluding Remarks Riad Sherif, M.D. Chief Executive Officer 5mn 01 02 03 04 05 06

To drive innovation to save sight and

improve eye care Our Purpose

2023 2024 OCS-01 is based on the

OPTIREACH technology, OCS-02 is a single chain antibody fragment (ScFv) against TNF and OCS-05 is a SGK-2 activator peptidomimetic small molecule with novel MoA targeting the activation of the trophic factor pathways. (1) Geographic

Atrophy (GA). (2) Diabetic Retinopathy (DR). (3) Age-related Macular Degeneration (AMD). (4) Retinal Vein Occlusion (RVO). Product Candidate Investigational Indication(s) Pre-clinical Phase 1 Phase 2 Phase 3 OCS-01 OPTIREACH technology OCS-02

Topical TNF Inhibitor OCS-05 SGK2 Activator OCS-03 (Undisclosed) DIABETIC MACULAR EDEMA INFLAMMATION AND PAIN FOLLOWING OCULAR SURGERY DRY EYE DISEASE UVEITIS ACUTE OPTIC NEURITIS CORNEAL NV, PTERYGIUM WET-AMD(3), RVO(4), DR GLAUCOMA, GA(1),

DR(2) OCS-04 CORNEAL TRANSPLANT CYSTOID MACULAR EDEMA Oculis is Uniquely Positioned to Build Significant Value Catalysts NEUROTROPHIC KERATITIS 1 endpt. met Stage 1 Ph 3 readout NDA PoC readout Ph 2b readout Ph 2b readout PoC readout With a

multi-assets, Late-stage Pipeline and near-term Catalysts Ph3 Stage 2

OCS-01 OPTIREACH enables eye

drops treating retinal disease: Two Phase 3 programs: DME, Ocular Surgery and PoC in CME Topical Diabetic Macular Edema and Cystoid Macular Edema treatment candidate based on Optireach technology with consistent positive & significant clinical

readouts OCS-05 Promising neuroprotective agent for neuro-retina diseases PoC in Acute Optic Neuritis, with multiple additional applications SGK-2 activator with neuroprotective potential for Glaucoma, Geographic Atrophy, Diabetic Retinopathy &

Neurotrophic Keratitis Cyclodextrin Drug molecule Single complex Complex aggregate water-soluble nanoparticle To address neurological damage Clinical Retina Programs Addressing Highly Meaningful Unmet Needs

OCS-01 delivered consistent positive

results in previous DME trials DME Exploratory 12 19 pts Tanito Study successfully completed DME Phase 24 144 pts Randomized & double-masked successfully completed DME Exploratory 23 22 pts Ohira Study successfully completed Positive results in

exploratory and Phase 2 studies in DME Unique product candidate with clinically validated MoA Phase 3 program initiated after positive Phase 2 results & EoP2 meeting OCS-01: High-concentration OPTIREACH formulation of dexamethasone (15

mg/ml) Change in BCVA & CST in Phase 2 Trial (Same Patient Population as Ph 3 DIAMOND Trial) OPTIREACH Formulation Technology Ozurdex , an IVT implant of dexamethasone, is FDA-approved for DME and annualizing at $460M and 7% growth1

Mean Change in BCVA From Baseline Mean Change in CST From Baseline ( m) 1. Abbvie Q1 2023 earnings report 2. Investigator-initiated, open-label, single-center study. Tanito M, et al. Invest Ophthalmol Vis Sci. 2011;52:7944-7948 3. Ohira A, et

al. Acta Ophthalmologica. 2015;93:610-615. Ohira A, et al. Acta Ophthalmologica. 2015;93:610-615. 4. DME Phase 2: Note: Data presented at Angiogenesis, Exudation and Degeneration, 2020 by KOL (Dugel P.) 5. Dugel PU. The Oculis OCS-01 phase 1/2

study: an effective topical therapeutic for DME. Presented at: Angiogenesis, Exudation, and Degeneration 2020; Feb. 8, 2020; Miami Central macular thickness (CMT); Best-corrected visual acuity (BCVA) visual acuity (BCVA); Dugel PU. The Oculis OCS-01

phase 1/2 study: an effective topical therapeutic for DME. Presented at: Angiogenesis, Exudation, and Degeneration 2020; Feb. 8, 2020; Miami. OCS-01 | First Eye Drop for DME

Unmet Needs DME Treatment Algorithm

Patient presents with DME symptoms Diagnosed by OCT(1) Current Treatment Observation Laser Anti-VEGF Steroid implant Laser 1st line 1st line 24% DME recent onset DME with mild visual impairment 43% 33% DME with moderate to severe visual impairment

DME Disease Progression and Treatment Landscape (1) Optical coherence tomography (OCT) imaging. (2) Baseline Demographics and Clinical Characteristics of Treatment-Na ve Patients with Diabetic Macular Edema Listed in the IRIS Registry (Table

S1) www.aao.org (3) Baker, Carl W., et al. "Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a

randomized clinical trial." Jama 321.19 (2019): 1880-1894. (4) Gonzalez 2016 Early and Long-term Responses to VEGF Therapy in DME: Analysis of protocol I data (5) Kiss 2014 ; Berenger and Kiss, Feb. 2016, Real-world Utilization of VEGF agents (DME

section), Review of Ophthalmology https://www.reviewofophthalmology.com/article/realworld-utilization-of-antivegf-agents (6) Decision Resources Group: DME - DR Landscape Forecast - Disease Landscape Forecast 2020 Disease Landscape

Forecast 2020 and Third parties research ( Akceso and Clearview) (2) (2) (2) 1 X Lack of pre-invasive treatment ~ 19% of patients with good vision experience deterioration by 5 letters over 2 years(3) X 40% Inadequate response Low anti-VEGF

response rate(5) Combination to drive efficacy and or durability 60% Adequate response 1 2 3 Expands patient and prescriber base First-line treatment New treatment option Addressable US patient population: 1.2 million(4)(6) OCS-01 | with the

potential to address all DME patients Unchanged

Stage 1 Recap and Next Steps Arshad M.

Disclosures - Arshad M. Khanani,

MD, MA, FASRS Consultant: AbbVie, Adverum, Aerie, Applied Genetics Technologies Corporation, Aldebaran, Allergan, Apellis, Arrowhead, Aviceda Therapeutics, Bausch + Lomb, Broadwing Bio, Clearside, 4D Molecular Therapeutics, Exgenesis, EyePoint,

Frontera, Genentech, Inc., Gyroscope, iLumen, Iveric Bio, Janssen, Kato, Kartos, Kodiak Sciences, Kriya, Ocular Therapeutix, Oculis, OcuTerra, Olives Bio, Opthea, Oxurion, Nanoscope, Notal, Novartis, Perfuse, PolyPhotonix, Protagonist, Ray

Therapeutics, RecensMedical, Regeneron, Regenxbio, Roche, RevOpsis, Stealth, Thea, Unity, Vanotech, Vial; Research Support: Adverum, Annexon, Apellis, 4D Molecular Therapeutics, Genentech, Inc., Gyroscope, Iveric Bio, Kodiak, Neurotech, NGM Bio,

Novartis, Ocular Therapeutix, Oculis, OcuTerra, Opthea, Oxurion, Regenxbio, Roche, Unity

Loading dose regimen & enriched

population increase probability of success Washout (if needed): 3 - 6 months depending on prior treatment 2:1 Randomization Stage 1: determine dose & sample size for Stage 2 Stage 2: dose regimen and sample size informed by Stage 1 results 2:1

Stage 1 (N = 148) Stage 2 (N = 350 - 450 per trial; 1:1 Randomization) Key Enrollment Criteria Age 18-85 years Diabetes mellitus 1 and 2 ETDRS BCVA letter score: 24 - 65 Retinal thickness (CST) 310 m Anti-VEGF and corticosteroid

na ve or agree to washout R OCS-01: 6x/day weeks 1 - 6; 3x/day weeks 7 - 52 Vehicle: 6x/day weeks 1 - 6; 3x/day weeks 7 - 52 OCS-01 6x/day OCS-01 3x/day Vehicle 6x/day Vehicle 3x/day Stage 1: Assess if loading dose optimizes efficacy 1

endpoint: Change in BCVA ETDRS letter score at wk 6 2 endpoint: % with a 3-line (15 letters) gain in BCVA at wk 6 2 endpoint: Change in CST as measured by SD-OCT(1) at wk 6 2 endpoint: Change in BCVA at wk 12 Stage 2:

Two Phase 3's to support NDA filing for DME 1 endpoint: BCVA at wk 52 Key 2 endpoint: 3-line (15 letters) at wk 52 2 endpoint: CST at wk 52 6 weeks 6 weeks 52 weeks End of Trial OCS-01 | Phase 3 Program in DME

Patients (1) Spectral Domain Optical Coherence Tomography .

Loading dose regimen & enriched

population increase probability of success Washout (if needed): 3 - 6 months depending on prior treatment 2:1 Randomization 6-week loading phase followed by 6-week maintenance phase Assessments at baseline, weeks 2, 4, 6, 8, and 12 2:1 Key

Enrollment Criteria Age 18-85 years Diabetes mellitus 1 and 2 ETDRS BCVA letter score: 24 - 65 Retinal thickness (CST) 310 m Anti-VEGF and corticosteroid na ve or agree to washout R OCS-01 6x/day OCS-01 3x/day Vehicle 6x/day

Vehicle 3x/day Stage 1 : Assess if loading dose optimizes efficacy 1 endpoint: Change in BCVA ETDRS letter score at wk 6 2 endpoint: % with a 3-line (15 letters) gain in BCVA at wk 6/12 2 endpoint: Change in CST as

measured by SD-OCT(1) at wk 6/12 2 endpoint: Change in BCVA at wk 12 6-week Loading Phase 6-week Maintenance Phase n = 100 n = 48 End of Stage 1 1 endpoint assessment OCS-01 | Phase 3 in DME Patients - Stage 1 (1) Spectral Domain

Optical Coherence Tomography .

AE, adverse event; ITT,

intention-to-treat. Data, analysis, and conclusions are preliminary, and subject to change as full analysis is ongoing. Patient Disposition ITT population Screened n = 288 Screen failures n = 140 OCS-01 n = 100 Vehicle n = 48 Completed 12 weeks n =

85 (85.0 %) Completed 12 weeks n = 39 (81.3 %) Discontinued study Withdrawn: n = 3 AE: n = 5 Other: n = 4 Discontinued study Withdrawn: n = 1 AE: n = 9 Other: n = 5 Randomized n = 148

Demographics: Well-balanced Between

Arms (1) Intraocular pressure. Data, analysis and conclusions are preliminary, and subject to change as full analysis is ongoing. . Parameter OCS-01 (n = 100) Vehicle (n = 48) Age, mean (SD), years 61.9 (9.0) 63.9 (7.3) Male, n (%) 53 (53.0) 26

(54.2) Duration of DME, mean (SD), years 2.0 (2.6) 1.9 (2.7) BCVA, mean (SD), ETDRS letter score 57.5 (9.3) 58.3 (7.5) CST, mean (SD), m 453.0 (131.8) 445.3 (112.5) IOP(1), mean (SD), mmHg 15.3 (3.1) 14.7 (3.0)

Primary Endpoint Achieved with

Robust Statistical Significance Rapid improvement in vision with OCS-01 treatment, as assessed by BCVA Strong Improvement in Vision with OCS-01 at Week 6 (95% CI, 1.1-7.0) OCS-01 Vehicle P = 0.007 Loading Phase (week 6), ITT Population BCVA, best

corrected visual acuity; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Study; ITT, intention-to-treat; LS, least squares; SE, standard error. Multiple imputations for missing data. Imputation rules are applied based on a

pattern-mixed model approach. Data, analysis and conclusions are preliminary, and subject to change as full analysis is ongoing.

Loading Phase (6x/day) Maintenance

Phase (3x/day) Improvement in Vision with OCS-01 Sustained to Week 12 Rapid improvement in BCVA with loading dose regimen sustained with maintenance regimen BCVA, best corrected visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study; ITT,

intention-to-treat; SD, standard deviation; SE, standard error. Multiple imputations for missing data. Imputation rules are applied based on a pattern-mixed model approach. Data, analysis and conclusions are preliminary, and subject to change as

full analysis is ongoing. (95% CI, 0.7-7.0) P = 0.016 ITT Population (95% CI, 1.1-7.0) P = 0.007

25% of OCS-01 Patients Achieve

3 Line Improvement in BCVA at Week 6 Vision Gainers Analysis at Week 6 3-line (15 letter) improvement in BCVA deemed highly clinically relevant 15-Letter Gain P = 0.015 ETDRS, Early Treatment Diabetic Retinopathy Study; ITT,

intention-to-treat. Data, analysis and conclusions are preliminary, and subject to change as full analysis is ongoing. ITT Population

27% of OCS-01 Patients with

3-Line Improvement in BCVA at Week 12 Vision Gainers Analysis at Week 12 3-line (15 letter) improvement in BCVA deemed highly clinically relevant 15-Letter Gain OCS-01 Vehicle P = 0.009 ETDRS, Early Treatment Diabetic Retinopathy Study; ITT,

intention-to-treat. Data, analysis and conclusions are preliminary, and subject to change as full analysis is ongoing. ITT Population

63.6 m Reduction in CST

Achieved with OCS-01 at Week 6 CST as Assessed by Optical Coherence Tomography (OCT) Central subfield thickness (CST) is a key metric used by physicians to manage DME patients (95% CI, -97.7, -40.5) P < 0.0001 OCS-01 Vehicle CI, confidence

interval; CST, central subfield thickness; ITT, intention-to-treat; LS, least squares; SE, standard error. Multiple imputations for missing data. Imputation rules are applied based on a pattern-mixed model approach. Data, analysis and conclusions

are preliminary, and subject to change as full analysis is ongoing. Loading Phase (week 6), ITT Population

Maintenance Phase (3x/day) Loading

Phase (6x/day) Reduction in CST Achieved with OCS-01 Sustained to Week 12 CST as Assessed by Optical Coherence Tomography (OCT) Rapid improvements in CST with loading dose regimen sustained with maintenance regimen (95% CI, -76.8, -14.4) P = 0.004

(95% CI, -97.7, -40.5) P < 0.0001 BCVA, best corrected visual acuity; CI, confidence interval; ETDRS, Early Treatment Diabetic Retinopathy Study; ITT, intention-to-treat; LS, least squares; SE, standard error. imputations for missing data.

Imputation rules are applied based on a pattern-mixed model approach. Data, analysis and conclusions are preliminary, and subject to change as full analysis is ongoing.

No Unexpected Safety Findings

Treatment Emergent Adverse Events OCS-01 (N = 100) n (%) Vehicle (N = 48) n (%) Any TEAE 70 (70.0) 30 (62.5) Diabetic retinal edema 10 (10.0) 9 (18.8) Intraocular pressure increased 14 (14.0) 1 (2.1) Hypertension 10 (10.0) 1 (2.1) Ocular